THE EFFECT OF PCSK9 INHIBITION ON LDL-SUBFRACTIONS IN PATIENTS WITH SEVERE LDL-HYPERCHOLESTEROLEMIA

Liya Wu,Charlotte Bamberger,Elisa Waldmann,Renee Stark,Kerstin Henze, Klaus G. Parhofer

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2017）

引用 2|浏览6

暂无评分

摘要

Background: PCSK9 inhibitors (PCSK9i) decrease LDL-cholesterol by ∼50% in hypercholesterolemia. However, it is unclear whether PCSK9i decrease all LDL-subfractions equally. Methods: We evaluated the effect of PCSK9i on LDL-subfractions in 16 patients (63±11y, BMI 29.9±5.0kg/m2) with coronary

查看译文

关键词

ldl-subfractions,ldl-hypercholesterolemia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要